Publications
Publications by STAR Researchers
Improved Splenic Function After Hematopoietic Stem Cell Transplant for Sickle Cell Disease. Nickel RS, Seashore E, Lane PA, Alazraki AL, Horan JT, Bhatia M, Haight AE. Pediatr Blood Cancer. 2016 May;63(5):908-13. http://www.ncbi.nlm.nih.gov/pubmed/26757445
Haematopoietic stem cell transplantation for sickle cell disease – current practice and new approaches. Arnold SD, Bhatia M, Horan J, Krishnamurti L. Br J Haematol. 2016 Jun 2. http://www.ncbi.nlm.nih.gov/pubmed/27255787
Can Preconsent Eliminate Some Barriers to Clinical Trial Enrollment of Children With Sickle Cell Disease in Crisis? Guilcher GM. Pediatr Blood Cancer. 2016 May 16. http://www.ncbi.nlm.nih.gov/pubmed/2718980
Successful matched sibling donor marrow transplantation following reduced intensity conditioning in children with hemoglobinopathies. King AA, Kamani N, Bunin N, Sahdev I, Brochstein J, Hayashi RJ, Grimley M, Abraham A, Dioguardi J, Wah Chan K, Douglas D, Adams R, Andreansky M, Anderson E, Gilman A, Chaudhury S, Yu L, Dalal J, Hale G, Cuvelier G, Jain A, Krajewski J, Gillio A, Kasow KA, Delgado D, Hanson E, Murray L, Shenoy S. Am J Hematol. 2015 Dec;90(12):1093-8. http://www.ncbi.nlm.nih.gov/pubmed/26348869
Red blood cell transfusions are associated with HLA class I but not H-Y alloantibodies in children with sickle cell disease. Nickel RS, Hendrickson JE, Yee MM, Bray RA, Gebel HM, Kean LS, Miklos DB, Horan JT. Br J Haematol. 2015 Jul;170(2):247-56. http://www.ncbi.nlm.nih.gov/pubmed/25891976
Allogeneic donor availability for hematopoietic stem cell transplantation in children with sickle cell disease. Justus D, Perez-Albuerne E, Dioguardi J, Jacobsohn D, Abraham A. Pediatr Blood Cancer. 2015 Jul;62(7):1285-7 http://www.ncbi.nlm.nih.gov/pubmed/25663074
Hematopoietic stem cell transplantation in sickle cell disease: patient selection and special considerations. Bhatia M, Sheth S. J Blood Med. 2015 Jul 10;6:229-38. http://www.ncbi.nlm.nih.gov/pubmed/26203293
Current attitudes of parents and patients toward hematopoietic stem cell transplantation for sickle cell anemia. Meier ER, Dioguardi JV, Kamani N. Pediatr Blood Cancer. 2015 Jul;62(7):1277-84. http://www.ncbi.nlm.nih.gov/pubmed/25809231
Allogeneic Hematopoietic Cell Transplantation for Children with Sickle Cell Disease Is Beneficial and Cost-Effective: A Single-Center Analysis. Arnold SD, Jin Z, Sands S, Bhatia M, Kung AL, Satwani P. Biol Blood Marrow Transplant. 2015 Jul;21(7):1258-65. http://www.ncbi.nlm.nih.gov/pubmed/25615608
Using fludarabine to reduce exposure to alkylating agents in children with sickle cell disease receiving busulfan, cyclophosphamide, and antithymocyte globulin transplant conditioning: results of a dose de-escalation trial. Horan JT, Haight A, Dioguardi JL, Brown C, Grizzle A, Shelman C, Kanter J, Hale G, Nieder M, Benton M, Kasow KA, Abraham A, Chiang KY. Biol Blood Marrow Transplant. 2015 May;21(5):900-5. http://www.ncbi.nlm.nih.gov/pubmed/25617808
Health-related quality of life after allogeneic hematopoietic stem cell transplantation for sickle cell disease. Bhatia M, Kolva E, Cimini L, Jin Z, Satwani P, Savone M, George D, Garvin J, Paz ML, Briamonte C, Cruz-Arrieta E, Sands S. Biol Blood Marrow Transplant. 2015 Apr;21(4):666-72. http://www.ncbi.nlm.nih.gov/pubmed/25559691
Autoimmune thyroid disease following alemtuzumab therapy and hematopoietic cell transplantation in pediatric patients with sickle cell disease. Williams KM, Dietzen D, Hassoun AA, Fennoy I, Bhatia M. Pediatr Blood Cancer. 2014 Dec;61(12):2307-9. http://www.ncbi.nlm.nih.gov/pubmed/24938636
The ethics of a proposed study of hematopoietic stem cell transplant for children with “less severe” sickle cell disease. Nickel RS, Hendrickson JE, Haight AE. Blood. 2014 Aug 7;124(6):861-6. http://www.ncbi.nlm.nih.gov/pubmed/24963044
Reduced toxicity, myeloablative conditioning with BU, fludarabine, alemtuzumab and SCT from sibling donors in children with sickle cell disease. Bhatia M, Jin Z, Baker C, Geyer MB, Radhakrishnan K, Morris E, Satwani P, George D, Garvin J, Del Toro G, Zuckerman W, Lee MT, Licursi M, Hawks R, Smilow E, Baxter-Lowe LA, Schwartz J, Cairo MS. Bone Marrow Transplant. 2014 Jul;49(7):913-20. http://www.ncbi.nlm.nih.gov/pubmed/24797180
Evidence-based focused review of the status of hematopoietic stem cell transplantation as treatment of sickle cell disease and thalassemia. King A, Shenoy S. Blood. 2014 May 15;123(20):3089-94; quiz 3210. http://www.ncbi.nlm.nih.gov/pubmed/24511087
Sickle cell disease: time for a closer look at treatment options? Sheth S, Licursi M, Bhatia M. Br J Haematol. 2013 Aug;162(4):455-64. http://www.ncbi.nlm.nih.gov/pubmed/23772687
Bone Marrow Derived Mesenchymal Stromal Cells From Sickle Cell Disease Patients Display Intact Functionality. Stenger EO, Chinnadurai R, Yuan S, Garcia M, Arafat D, Gibson G, Krishnamurti L, Galipeau J. Biol Blood Marrow Transplant. 2017. https://www.ncbi.nlm.nih.gov/pubmed/28132869
Current Results and Future Research Priorities in Late Effects after Hematopoietic Stem Cell Transplantation for Children with Sickle Cell Disease and Thalassemia: A Consensus Statement from the Second Pediatric Blood and Marrow Transplant Consortium International Conference on Late Effects after Pediatric Hematopoietic Stem Cell Transplantation. Shenoy S, Angelucci E, Arnold SD, Baker KS, Bhatia M, Bresters D, Dietz AC, De La Fuente J, Duncan C, Gaziev J, King AA, Pulsipher MA, Smith A, Walters MC. Biol Blood Marrow Transplant. 2017. https://www.ncbi.nlm.nih.gov/pubmed/28065838
A trial of unrelated donor marrow transplantation for children with severe sickle cell disease. Shenoy S, Eapen M, Panepinto JA, Logan BR, Wu J, Abraham A, Brochstein J, Chaudhury S, Godder K, Haight AE, Kasow KA, Leung K, Andreansky M, Bhatia M, Dalal J, Haines H, Jaroscak J, Lazarus HM, Levine JE, Krishnamurti L, Margolis D, Megason GC, Yu LC, Pulsipher MA, Gersten I, DiFronzo N, Horowitz MM, Walters MC, Kamani N. Blood. 2016 Nov 24;128(21):2561-2567. https://www.ncbi.nlm.nih.gov/pubmed/27625358